Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brexpiprazole as Adjunctive Therapy in MDD
NCT02012218Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Nov 2013
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of brexpiprazole in major depressive disorder (MDD), sponsored by Otsuka Pharmaceutical Development & Commercialization. Started Nov 2013; status: completed.
02
Drugs
brexpiprazole
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02012218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02012218.